---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-136687"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:18:40.442338+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galera Q1 net loss narrows to $4.4M; ceases clinical development, explores strategic alternatives

## Summary
- Net loss of $4.4M ($0.08/sh) vs $17.7M ($0.50/sh) in Q1 2023; R&D expenses fell to $1.5M.
- Cash and equivalents $13.5M as of March 31, 2024; expected to fund operations into Q3 2025.
- Company ceased all clinical trial activity and suspended clinical development of avasopasem and rucosopasem.
- Board adopted stockholder rights agreement on May 3, 2024 in response to recent stock accumulations.
- Evaluating strategic alternatives with Stifel; options may include mergers, asset sales, or dissolution.

## SEC filing metadata
- accession: 0001193125-24-136687
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/0001193125-24-136687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/d802127d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-136687
- JSON: https://secwatch.observer/filing/0001193125-24-136687.json
- Plain text: https://secwatch.observer/filing/0001193125-24-136687.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $(4.4) million, or $(0.08) per share, EPS $(0.08) per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $(4.4) million, or $(0.08) per share
  - EPS: $(0.08) per share
  - Result: reported results
  source text: Galera reported a net loss of $(4.4) million, or $(0.08) per share, for the first quarter of 2024, compared to a net loss of $(17.7) million, or $(0.50) per share, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524136687/0001193125-24-136687-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.